Form 4: Director Sells UTHR Shares After Option Exercise

United Therapeutics Director Tommy G Thompson exercised stock options and subsequently sold an equal number of common shares on December 18, 2025.

Summary

• Director Tommy G Thompson of United Therapeutics Corp (UTHR) engaged in transactions on December 18, 2025.
• Exercised 910 stock options at an exercise price of $101.8 per share.
• Immediately sold 910 shares of common stock at a weighted average price of $500.5859 per share.
• Following these transactions, direct beneficial ownership of common stock is 8,480 shares.
• Indirect beneficial ownership includes 8,200 shares held by a Trust and 5,800 shares held by a Family LLC.
• Remaining derivative securities include 4,000 stock options.
• The reported common stock ownership includes 880 shares from deferred RSU vesting on July 7, 2023, which are expected to be issued around July 8, 2026.

Sentiment

Score: 6

Explanation: The director exercised options and sold shares, which is a common practice for compensation and liquidity. The sale at a significantly higher price than the exercise price is positive for the director, but the net effect on the company's outlook is neutral from this filing alone. It is not a strong positive or negative signal for the company's performance.

Positives

• The director exercised options, indicating value in the underlying stock at the exercise price.
• The sale price of $500.5859 is significantly higher than the exercise price of $101.8, indicating a substantial gain for the director.

Negatives

• A director selling shares, even as part of a planned compensation strategy, could be perceived negatively by some investors.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may observe the director's activity, which shows a director taking profits from exercised options. This is a routine transaction and does not necessarily indicate a change in company fundamentals.

Next Steps

• Issuance of 880 common shares around July 8, 2026, resulting from deferred RSU vesting.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction where a director exercised stock options and immediately sold the acquired shares. This is often part of a pre-planned compensation strategy or for personal liquidity and does not inherently signal a change in the company's fundamental outlook or performance. The significant difference between the exercise price and sale price indicates a profitable transaction for the director, but it does not provide new information to warrant a change in investment recommendation for the stock itself.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director Transaction, Tommy G Thompson, Beneficial Ownership